Abstract / Description of output
Ambrisentan is the second selective endothelin-A receptor antagonist to be licensed in Europe, and the first in the United States, for the management of pulmonary arterial hypertension (PAH). It has been shown to be clinically effective in improving exercise tolerance and functional class. Furthermore, ambrisentan is well tolerated and associated with low rates of liver toxicity and minimal interactions with other medicines commonly used to treat PAH. Overall, current data support a role for ambrisentan in the management of PAH. However, the results of longer-term follow-up studies are still required to fully assess efficacy and safety.
Original language | English |
---|---|
Pages (from-to) | 875-885 |
Number of pages | 11 |
Journal | Drugs of today |
Volume | 44 |
Issue number | 12 |
DOIs | |
Publication status | Published - Dec 2008 |